Meet ESSA’s Board of Directors

ESSA’s Board of Directors is comprised of successful decision-makers from a broad range of industries.

richard-glickman

Richard Glickman, L.L.D. (Hon)

Chairman of the Board

Dr. Glickman has served as Chairman of ESSA’s board of directors since October 2010, and is responsible for the management of the board of directors to ensure ESSA has appropriate objectives, an effective strategy and is operating in accordance with a high standard of corporate governance. Dr. Glickman presently serves as the CEO and Chairman of the Board of Aurinia Pharmaceuticals. He was also a co-founder, Chairman and CEO of Aspreva Pharmaceuticals Inc. Prior to establishing Aspreva, Dr. Glickman was the co-founder and CEO of StressGen Biotechnologies Corporation. Dr. Glickman currently serves on the board of directors of Cardiome, Vida Pharmaceuticals and Engene Inc., and is Chairman of the board of directors of Aurinia Pharmaceuticals Inc. In addition, Dr. Glickman has served on many other biotechnology boards of directors. Dr. Glickman received the 2004 Ernst & Young Entrepreneur of the Year Award for the Pacific Region Life Sciences Group, both Canada’s and British Columbia’s Top 40 under 40 Award for Entrepreneurs, the 2006 BC Biotech Leadership Award and the Lupus Foundation of America Leadership Award.

Read More
david-parkinson

David R. Parkinson, MD

President, Chief Executive Officer & Director

Dr. Parkinson has served as a director of the Company since June 24, 2015 and has been employed full time as the President and Chief Executive Officer of the Company since January 7, 2016. He is responsible for the management of the Company, developing objectives, strategy and standards of performance, securing and leading a team of professionals and directing them to deliver the required performance. Most recently Dr. Parkinson has served as a venture partner at New Enterprise Associates (NEA), Inc., and following his assumption of these new Essa-related responsibilities he has moved to the role of venture advisor to NEA. From 2007 until 2012, Dr. Parkinson served as President and CEO of Nodality, a biotechnology company focused on the biological characterization of signaling pathways in patients with malignancy to enable more effective therapeutics development and clinical decision-making. Dr. Parkinson has previously led oncology clinical development activities at Novartis (1997-2003), Amgen (2003-2006) and Biogen Idec 2006-2007). He worked at the National Cancer Institute from 1990 to 1997, serving as Chief of the Investigational Drug Branch, and then as Acting Associate Director of the Cancer Therapy Evaluation Program (CTEP). Dr. Parkinson is a past Chairman of the Food & Drug Administration (FDA) Biologics Advisory Committee, has also served on the FDA’s Science Board, and is a recipient of the FDA’s Cody Medal. He has served on the National Cancer Policy Forum of the Institute of Medicine, as a board director for the Ontario Institute for Cancer Research, and is a past co-chair of the Cancer Steering Committee of the NIH Foundation Biomarkers Consortium. He currently serves as a Board Director for the Multiple Myeloma Research Foundation and has served as Chairperson of the American Association of Cancer Research (AACR) Finance and Audit Committee for the last 15 years. Dr. Parkinson was formerly a Director of Facet Biotech, Inc. and Ambit Biosciences, both public biopharma companies which were acquired by large pharma. He currently serves as Director on the Boards of Cerulean Pharma Inc., 3S Bio Inc. He has held academic positions both at Tufts and at the University of Texas MD Anderson Cancer Center, and has authored over 100 peer-reviewed publications.

Read More
gary-sollis

Gary Sollis, L.L.D.

Director

Mr. Sollis has served as an ESSA director since April 2012 and is a partner at the law firm of Dentons Canada LLP. He represents clients in the areas of corporate and securities law, with a focus on acquisitions, financings and reorganizations. He has acted for a variety of public and private companies in financing transactions, including public offerings, private placements of debt and equity, special warrant financings and public and private limited partnership offerings. Mr. Sollis has also assisted clients with takeover bids, mergers, proxy contests, spin-offs, joint ventures and acquisitions of private businesses. He received a Bachelor of Laws degree from Dalhousie University.

Read More
franklin-berger

Franklin Berger, CFA

Director

Mr. Berger spent 12 years in sell-side equity research, most recently as Managing Director, U.S. Equity Research at J. P. Morgan Securities, Inc. (“JPM”) from May 1998 to March 2003 where he was involved with the issuance of over $12 billion in biotechnology company equity or equity-linked securities. Mr. Berger was associated with several notable financings in the biotechnology sector including the Genentech Inc. initial public offering, the first large Celgene Corporation financings as well as financings of several large-cap biotechnology companies in their rapid growth phase. His team covered 26 publicly-traded biotechnology companies. Mr. Berger began his career as a sell-side analyst at Josephthal & Co. in 1991, subsequently moving to Salomon Smith Barney in 1997 serving as Director, Equity Research and Senior Biotechnology Analyst. Mr. Berger currently serves on the board of directors of three biotechnology companies: Five Prime Therapeutics, Inc., Immune Design Corp. and Bellus Health, Inc. Previous public company board service included 11 years with Seattle Genetics, Inc., 7 years with VaxGen, Inc. and Aurinia Pharmaceuticals Inc. (previously Isotechnika Pharma Inc.), based in Canada. He also serves or has served on biotech company boards of directors including iTherX Pharma, Inc., Caprion Proteomics Inc. and ViroChem Pharma, Inc. (purchased by Vertex Pharmaceuticals, Inc. for $400 million in 2009). Mr. Berger has led multiple M&A analyses resulting in greater than $1 billion in transaction value.

Read More
scott-requadt

Scott Requadt, JD, MBA

Director

Scott Requadt, JD, MBA, is currently a Managing Director at Clarus Ventures, a life sciences venture capital fund. Scott has over 15 years of operating and investment experience in the pharmaceutical industry. Prior to joining Clarus in 2005, Scott was Director, Business Development of TransForm Pharmaceuticals, and previously practiced for several years as an M&A attorney at the NYC-based law firm of Davis Polk & Wardwell. Before that, Scott was a law clerk for a senior judge at the Supreme Court of Canada. Scott holds a B.Com (Economics & Finance) from McGill University, an LL.B from University of Toronto and an MBA from Harvard Business School (Baker Scholar). Mr. Requadt has been involved in multiple investments spanning both therapeutics and medtech, including Intercept Pharmaceuticals and several R&D risk-sharing collaborations with large pharma partners. He has previously been active on the Boards of TyRx, Catabasis, Oxford Immunotec, VBI Vaccines, Link Medicine and Biolex Therapeutics.

Read More
marianne-sadar

Marianne D. Sadar, PhD

Director

Dr. Sadar co-founded ESSA in 2009. She is a BC Cancer Agency Distinguished Scientist and a UBC Professor of Pathology and Laboratory Medicine. Dr. Sadar is an international leader in developing therapeutics against the androgen receptor. Dr. Sadar received her B.Sc. from Simon Fraser University and her Ph.D. from the University of Bradford, U.K. Post-doctoral training was at AstraZeneca (Astra Hässle) and the BC Cancer Agency. She has served on 50 scientific panels including the integration panel of the U.S. Department of Defense Prostate Cancer Research Program. Dr. Sadar has received numerous awards such as the Terry Fox Young Investigator Award and SWIU/SBUR “Award for Excellence in Urologic Research”. She has acted as President of the Society of Basic Urologic Research and is a member of the Scientific Advisory Boards for the Prostate Cancer Foundation and the Coalition to Cure Prostate Cancer.

Read More
raymond-andersen

Raymond Andersen, PhD

Director

Dr. Andersen co-founded ESSA in 2009. He is a Professor of Chemistry at UBC and is internationally known for his research on marine natural products and their potential as drug leads. His discoveries have represented core technologies of Aquinox Pharmaceuticals and Inflazyme Pharmaceuticals and his industrial programs have led to deals with Aventis and Wyeth and the venture capital arms of Johnson & Johnson and Pfizer. Dr. Andersen received his B.Sc. from the University of Alberta, an M.Sc. from UC Berkeley, a Ph.D. from UC San Diego, and he was a post-doctoral Fellow at MIT. Dr. Andersen is a Fellow of the Royal Society of Canada and he has received the Chemical Institute of Canada Medal, the UBC Jacob Biely Research Prize, and the American Society of Pharmacognosy Farnsworth Award.

Read More